Julian Adams

Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.

Part of Takeda Pharmaceutical Co., Ltd., ProScript, Inc. is a private company that develops anti-cancer treatments. The company is based in Cambridge, MA. The company was founded by Tom Maniatis. ProScript was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on July 20, 1999 for $3.35 million.

Limulus Management Co. LLC is a venture capital firm founded by Lawrence Miller and Paul Howard in 1999. It is headquartered in Newton, Massachusetts.

Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT.

Predix Pharmaceuticals Holdings, Inc. is a pharmaceutical company focused on the discovery and development of novel, highly selective, small-molecule drugs that target G-Protein Coupled Receptors (GPCRs) and ion channels.

CureTech Ltd. operates as a biotechnology company. It develops novel and immune modulating products for the treatment and control of cancer. The company was founded by Michael Schickler in 1995 and is headquartered in Yavne, Israel.

Clal Biotechnology Industries Ltd. (Clal Biotechnology Industries) is a venture capital division of Clal Biotechnology Industries Ltd. founded in 1993. The firm is headquartered in Tel Aviv, Israel.

Warp Drive Bio, Inc. focused on proprietary genomic technology to discover drugs of natural origin. The firm deployed proprietary platforms Genome Mining and Small Molecule Assisted Receptor Targeting (SMART) to discover and develop novel molecules addressing new pharmacologic mechanisms. The company was founded by Gregory L. Verdine, George McDonald Church, and James A. Wells in 2012 and was headquartered in Cambridge, MA.

BioNTech US, Inc. develops novel therapeutics leveraging neoantigen biology to treat cancer. It offers NEO-PV-01, a personalized neoantigen vaccine that builds upon initial clinical trials. The company was founded by James P. Allison, Edward J. Fritsch, Nir Hacohen, Eric S. Lander, Robert Schreiber, Ton Schumacher and Catherine Wu on October 21, 2013 and is headquartered in Cambridge, MA.